Critical Q3 Scientific Milestones to lookout for:
VP-001:
- SAD Safety outcomes for Cohort 1
- Orphan Drug Designation (best case) / Application (worst case)
- Paediatric Drug Designation (best case) / Application (worst case)
PYC-001:
Natural History Study initiated
PYC-002:
Non-Clinical Data set completed (with a focus on efficacy) to support final CNS lead selection
Ann: Q3 Investor Call Advance Notice, page-9
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $629.9M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $919.8K | 7.025M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12715 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 276517 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |